Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > New Proactive Video
View:
Comment by Alamir1111 on Sep 03, 2024 6:51pm
Looked at the proactive video from 6 days ago and the one today kind wondering if those too forget to change wardrobe or today's video was recorded days ago?? 
Comment by Paradise818 on Sep 03, 2024 7:48pm
Good observation!   Roger must only wear green shirts.   Inquiring minds want to know. 
Comment by Tarbaby on Sep 03, 2024 8:11pm
Have they actually studied Ruvidar for HSV treatment in small animals or only on cells infected with the virus in vitro? Then from animals to humans is a big step. More details are needed to convince investors. In other words...show it... dont just say it. I truly hope its all real both for us investors and the public good.
Comment by N0taP00p on Sep 03, 2024 9:48pm
It feels like these petri dish type NRs are  generally stacked closer to PP phases in the hopes of attracting new buyers.  It's a guess...and probably what they need to do tactically anyway while waiting for BTD data.  It's great stuff but feels like years and years away from approval.  The Kool-Aid folks here can be useful and fact check this stacking of NRs, say back ...more  
Comment by CancerSlayer on Sep 04, 2024 12:27pm
Agree...we are in the early innings. Although Ruvidar is still in the research/preclinical stages for this HSV-1 indication, the in vitro testing was not a "solo" performance study, but was a head-to-head analysis against a SOC drug.  This differs from TLT's current Ph II NMIBC study which has basically been a "single-drug" study in vitro & in vivo.   ...more  
Comment by toade1313 on Sep 04, 2024 2:35pm
EARLY INNINGS?????   Some of us have been in this for many Decades. Game in a "Rain Delay" and tornado approaching. A small umbrella aint gonna help that much. 
Comment by Kayz88 on Sep 04, 2024 4:41pm
Lol agreed. We are already in OT 27th inning, audience is exhausted, food and drinks are running out. 
Comment by toade1313 on Sep 04, 2024 4:50pm
All pitchers used.  1st base coach warming up in the bullpen. Batboy catching his tosses. Out of respect for those that know much more than I, no guesses for BTD from me. 
Comment by CancerSlayer on Sep 04, 2024 6:21pm
Early innings of "HSV-1 research"...sorry for the unsettling confusion.
Comment by StevenBirch on Sep 04, 2024 7:33pm
I thought you were quite clear CS.
Comment by Gooseybear on Sep 04, 2024 3:16pm
My family members have used Acyclovir for years to combat cold sores caused by herpes simplex 2 which is from the chicken pox virus. There are millions of people who have had the chicken pox and it is triggered by various factors like stress, diet, sun exposure, illness. Who is next? Wouldn't you not like to have cold sores .
Comment by Longholder99 on Sep 04, 2024 6:23pm
I wonder if this could stop a chicken pox infections.  
Comment by CancerSlayer on Sep 04, 2024 7:12pm
Chicken pox is also a member of the Herpes Virus family & hence shares similar characteristics (i.e. enveloped, double-stranded DNA virus)...just presents with different clinical manifestations.  Based on Dr. Coombs' earlier in vitro research, one can at least make an educated guess that what works against HSV-1 has a good chance of working against Chicken Pox as well....though ...more  
Comment by Johnandrose22 on Sep 04, 2024 7:37pm
Oh, Cancerslayer...your data driven image is, indeed, powerful....Perhaps our small, seemingly insignificant company will be the Say Hey Kid of healthcare....I saw Willie Mays play...a relatively small run of the mill player like so many...until he got up to bat!....I've never seen a baseball rocket out of a field until I saw Willie....I've understood what TLD1433/Ruvidar can do....OK, FDA ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250